Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04607837 · ClinicalTrials.gov registry record · Phase 2
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT04607837 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 234 participants.
The verdict
NCT04607837, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
Interventions
- DRUG Placebo
- DRUG Etrasimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04607837
The ClinicalTrials.gov registry entry for NCT04607837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04607837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04607837 about?
NCT04607837 is a clinical study titled "Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis". The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
What is the current status of trial NCT04607837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2021-04-12. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT04607837?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT04607837?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.